{
  "question_stem": {
    "en": "A 64-year-old man comes to the office for follow-up of hypertension. At the last 2 visits, his blood pressure was persistently elevated. The patient has been treated with lisinopril for the past 5 years, but his other blood pressure medications have been changed several times due to various adverse effects. Medical history is significant for type 2 diabetes mellitus, coronary artery disease with stable angina, and moderately increased albuminuria. Blood pressure is 145/87 mm Hg and pulse is 70/min. BMI is 31 kg/m². Physical examination shows trace bilateral lower extremity edema. ECG is unremarkable. Serum laboratory results are as follows:\n\nSodium 138 mEq/L\nPotassium 5.3 mEq/L\nChloride 104 mEq/L\nBicarbonate 24 mEq/L\nCalcium 9.5 mg/dL\nCreatinine 1.0 mg/dL\n\nReview of the patient's medical records shows similar serum laboratory results 6 months ago.",
    "zh": "一名64岁男性前来就诊，进行高血压复诊。在最近的两次就诊中，他的血压持续升高。患者过去5年来一直使用赖诺普利治疗，但由于各种不良反应，他的其他降压药物已更换过几次。病史显著包括2型糖尿病、伴有稳定型心绞痛的冠状动脉疾病以及中度蛋白尿。血压为145/87 mmHg，脉搏70次/分。BMI为31 kg/m²。体格检查显示双侧下肢轻度水肿。心电图无特殊发现。血清实验室检查结果如下：\n\n钠138 mEq/L\n钾5.3 mEq/L\n氯104 mEq/L\n碳酸氢盐24 mEq/L\n钙9.5 mg/dL\n肌酐1.0 mg/dL\n\n对患者病历的回顾显示，6个月前的血清实验室检查结果类似。"
  },
  "question": {
    "en": "Which of the following medications should be avoided in this patient?",
    "zh": "该患者应避免使用以下哪种药物？"
  },
  "options": {
    "A": {
      "en": "Amlodipine",
      "zh": "氨氯地平"
    },
    "B": {
      "en": "Bumetanide",
      "zh": "布美他尼"
    },
    "C": {
      "en": "Diltiazem",
      "zh": "地尔硫卓"
    },
    "D": {
      "en": "Eplerenone",
      "zh": "依普利酮"
    },
    "E": {
      "en": "Furosemide",
      "zh": "呋塞米"
    },
    "F": {
      "en": "Metoprolol",
      "zh": "美托洛尔"
    }
  },
  "correct_answer": "D",
  "explanation": {
    "en": "Mineralocorticoid receptor blockers (eg, spironolactone, eplerenone), angiotensin II receptor blockers (eg, losartan), and epithelial sodium channel blockers (eg, amiloride, triamterene) are other antihypertensives that can raise potassium levels. Concurrent use with an ACE inhibitor can result in severe hyperkalemia and should be avoided in this patient with mild hyperkalemia at baseline.\n\n(Choices A and C) Dihydropyridine calcium channel blockers (eg, amlodipine, nifedipine) inhibit the L-type calcium channel on vascular smooth muscle, leading to arterial vasodilation. Nondihydropyridine calcium channel blockers (eg, verapamil) reduce heart rate and contractility. Diltiazem causes both vasodilation and decreased heart rate and contractility. Calcium channel blockers do not cause significant electrolyte abnormalities and may be used in patients at risk for hyperkalemia. Although dihydropyridine calcium channel blockers may cause lower extremity edema, trace pedal edema is extremely common and not a contraindication for use.\n\n(Choices B and E) Loop diuretics (eg, bumetanide, furosemide) inhibit the Na+/K+/2Cl- symporter in the ascending limb of the loop of Henle. They decrease intravascular volume, leading to an increase in serum aldosterone and a resultant increase in urinary potassium excretion, causing hypokalemia.\n\n(Choice F) Metoprolol is a selective beta-1 blocker that decreases heart rate, cardiac contractility, and renin release, which reduces arterial blood pressure and myocardial oxygen demand. Although nonselective beta blockers (eg, carvedilol) can cause hyperkalemia by inhibiting beta-2–mediated intracellular potassium uptake, this does not typically occur with selective beta-1 blockers. Although beta blockers can mask hypoglycemia in diabetic patients, this is not a contraindication and they can still be used (cautiously) in patients with CAD to reduce myocardial oxygen demand.\n\nEducational objective:\nACE inhibitors block the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. Decreased aldosterone leads to potassium retention, which can cause hyperkalemia, especially in patients with renal insufficiency and those taking other medications that raise potassium levels (eg, angiotensin II receptor blockers, mineralocorticoid receptor blockers).",
    "zh": "盐皮质激素受体阻滞剂（例如，螺内酯、依普利酮）、血管紧张素II受体阻滞剂（例如，氯沙坦）和上皮钠通道阻滞剂（例如，阿米洛利、氨苯蝶啶）是其他可升高钾水平的降压药。与ACE抑制剂同时使用可导致严重的 高钾血症，并且应避免用于基线轻度高钾血症的患者。\n\n（选项A和C）二氢吡啶类钙通道阻滞剂（例如，氨氯地平、硝苯地平）抑制血管平滑肌上的L型钙通道，导致动脉血管舒张。非二氢吡啶类钙通道阻滞剂（例如，维拉帕米）降低心率和收缩力。地尔硫卓既引起血管舒张，又降低心率和收缩力。钙通道阻滞剂不会引起明显的电解质异常，可用于有高钾血症风险的患者。虽然二氢吡啶类钙通道阻滞剂可引起下肢水肿，但轻微的足部水肿非常常见，并非使用的禁忌症。\n\n（选项B和E）袢利尿剂（例如，布美他尼、呋塞米）抑制亨利袢升支中的Na+/K+/2Cl-协同转运蛋白。它们降低血管内容量，导致血清醛固酮升高，并导致尿钾排泄增加，从而导致低钾血症。\n\n（选项F）美托洛尔是一种选择性β-1受体阻滞剂，可降低心率、心肌收缩力和肾素释放，从而降低动脉血压和心肌耗氧量。虽然非选择性β受体阻滞剂（例如，卡维地洛）可通过抑制β-2介导的细胞内钾摄取引起高钾血症，但这通常不会发生在选择性β-1受体阻滞剂上。虽然β受体阻滞剂可掩盖糖尿病患者的低血糖，但这并非禁忌症，并且仍可（谨慎地）用于CAD患者以减少心肌耗氧量。\n\n教学目标：\nACE抑制剂可阻断血管紧张素I转化为血管紧张素II，从而减少血管收缩和醛固酮分泌。醛固酮降低导致钾潴留，可引起高钾血症，尤其是在肾功能不全的患者和服用其他可升高钾水平的药物（例如，血管紧张素II受体阻滞剂、盐皮质激素受体阻滞剂）的患者中。"
  },
  "summary": {
    "en": "This question tests the knowledge of drug interactions and the potential for hyperkalemia in patients taking ACE inhibitors. It requires understanding the mechanisms of action of different antihypertensive medications and their effects on potassium levels.\n\nThe best approach is to identify the patient's risk factors for hyperkalemia (ACE inhibitor use, mild hyperkalemia) and then consider which medications could exacerbate this condition. Mineralocorticoid receptor blockers like eplerenone are known to increase potassium levels and should be avoided in this patient.",
    "zh": "此题考察了对药物相互作用的知识以及服用ACE抑制剂的患者发生高钾血症的潜在风险。它要求理解不同降压药物的作用机制及其对钾水平的影响。\n\n最好的方法是识别患者高钾血症的危险因素（使用ACE抑制剂、轻度高钾血症），然后考虑哪些药物会加剧这种情况。已知依普利酮等盐皮质激素受体阻滞剂会增加钾水平，应避免用于该患者。"
  },
  "tags": "Hyperkalemia; ACE inhibitors; Mineralocorticoid receptor blockers; Drug interactions; Hypertension; Potassium; Endocrinology; Nephrology; Cardiology",
  "category": "CVS",
  "question_id": "697",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\697",
  "extracted_at": "2025-11-05T12:15:25.748315",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:30:49.787915",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}